SEC Filing | Blueprint Medicines Corp.

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lee Philina

(Last)

(First)

(Middle)

C/O BLUEPRINT MEDICINES CORPORATION

45 SIDNEY STREET

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/04/2022

3. Issuer Name and Ticker or Trading Symbol
Blueprint Medicines Corp [ BPMC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	20,354⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	08/18/2024	Common Stock	261	1.87	D
Stock Option (Right to Buy)	⁽²⁾	02/10/2025	Common Stock	523	8.8	D
Stock Option (Right to Buy)	⁽²⁾	02/03/2026	Common Stock	1,224	15.01	D
Stock Option (Right to Buy)	⁽²⁾	02/16/2027	Common Stock	157	36.05	D
Stock Option (Right to Buy)	⁽²⁾	07/03/2027	Common Stock	1,042	51.06	D
Stock Option (Right to Buy)	⁽²⁾	02/16/2028	Common Stock	5,011	81.44	D
Stock Option (Right to Buy)	⁽³⁾	03/01/2029	Common Stock	12,350	86.6	D
Stock Option (Right to Buy)	⁽⁴⁾	03/01/2030	Common Stock	8,450	54.13	D
Stock Option (Right to Buy)	⁽⁵⁾	03/01/2031	Common Stock	8,650	100.13	D
Stock Option (Right to Buy)	⁽⁶⁾	03/01/2032	Common Stock	17,500	61.31	D

Explanation of Responses:

1. The number reported includes restricted stock units previously granted to the Reporting Person.

2. This option is fully vested and exercisable as of the date hereof.

3. This option vests in forty-eight equal monthly installments, with the first installment vested on April 1, 2019.

4. This option vests in forty-eight equal monthly installments, with the first installment vested on April 1, 2020.

5. This option vests in forty-eight equal monthly installments, with the first installment vested on April 1, 2021.

6. This option vests in forty-eight equal monthly installments, with the first installment vested on April 1, 2022.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ariel Hurley, Attorney-in-Fact	04/14/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

ex24-04142022_010422.htm

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Tracey McCain, Ariel Hurley and Michael Landsittel, and each of them individually, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

(1)

Complete and execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer, director and/or ten percent (10%) shareholder of Blueprint Medicines Corporation, a Delaware corporation (the “Company”) any and all instruments, certificates and documents required to be executed on behalf of the undersigned as an individual or on behalf of the undersigned’s company or partnership, as the case may be, pursuant to Section 13 and Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or the rules and regulations thereunder;

(2)

Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such instruments, certificates or documents required to be filed pursuant to Sections 13 and 16 of the Exchange Act or the rules or regulations thereunder and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3)

Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act which is necessary, proper or desirable to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that any such attorney-in-fact, or any such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 13 or Section 16 of the Exchange Act or the rules or regulations thereunder. The undersigned hereby agrees to indemnify each attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to such attorney-in fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any instruments, certificates and documents pursuant to Section 13 and 16 of the Exchange Act or the rules or regulations thereunder with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of January 19, 2022.

By: /s/ Philina Lee______________________

Name: Philina Lee